• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    5/16/25 4:00:00 PM ET
    $NRIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRIX alert in real time by email

    SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on May 13, 2025, the company granted inducement awards to thirteen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

    The company granted stock options to purchase an aggregate of 87,950 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 60,050 shares of Nurix common stock.

    One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee's date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee's date of hire, subject to the employee's continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of $9.73 per share, which is equal to the closing price of Nurix's common stock on the grant date as reported by the Nasdaq Global Market.

    One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is April 30, 2025, subject to the employee's continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee's continued service with Nurix on each such vesting date.

    About Nurix Therapeutics, Inc.

    Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix's dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine's next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

    Contacts:

    Investors

    Jason Kantor, Ph.D.

    Nurix Therapeutics, Inc.

    [email protected]

    Elizabeth Wolffe, Ph.D.

    Wheelhouse Life Science Advisors

    [email protected]

    Media

    Aljanae Reynolds

    Wheelhouse Life Science Advisors

    [email protected]



    Primary Logo

    Get the next $NRIX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NRIX

    DatePrice TargetRatingAnalyst
    3/17/2025$16.00Market Perform
    Leerink Partners
    12/10/2024$35.00Buy
    BTIG Research
    12/6/2024$35.00Outperform
    BMO Capital Markets
    10/24/2024$35.00Buy
    UBS
    10/11/2024$41.00Buy
    Jefferies
    9/6/2024$26.00Outperform
    Robert W. Baird
    7/31/2024$36.00Buy
    Truist
    6/26/2023$25.00Outperform
    Oppenheimer
    More analyst ratings

    $NRIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN FRANCISCO, May 16, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on May 13, 2025, the company granted inducement awards to thirteen new employees. The grants were made pursuant to Nurix's 2024 Equity Inducement Plan as an inducement material to the employees' acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix's Board of Directors i

      5/16/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

      SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 2:05 p.m. ET. The conference is being held in New York, NY. The fireside chat will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcast will be avail

      5/15/25 7:00:00 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

      Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company's proprietary DNA encoded library data Nurix's DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many targets considered undruggable, with the potential to accelerate the discovery of novel drugs SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today presented data that demonstrate the potential of its DEL Foundation Model to enable the rapid in silico identifi

      4/28/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

      SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      11/14/24 9:00:57 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

      SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      11/14/24 4:21:48 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nurix Therapeutics Inc.

      SC 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      11/14/24 4:08:39 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    SEC Filings

    See more

    $NRIX
    Leadership Updates

    Live Leadership Updates

    See more

    $NRIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

      SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      5/12/25 10:44:45 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

      SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      5/12/25 10:36:17 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Nurix Therapeutics Inc.

      SCHEDULE 13G/A - Nurix Therapeutics, Inc. (0001549595) (Subject)

      4/23/25 8:57:57 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M license extension fee from ongoing collaboration with SanofiEnhanced oversight and leadership team with the appointments of Roy D. Baynes to the Board and John Northcott as chief commercial officerWell capitalized with cash and marketable securities of $549.7 million SAN FRANCISCO, April 08, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medi

      4/8/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

      SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon Therapeutics, has had a distinguished career in hematology and oncology and over 22 years of clinical leadership experience in pharmaceutical and biotech companies. "Roy has been a trusted advisor to Nurix since 2023, and I am delighted to welcome him to our board

      3/13/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

      Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received PRIME designation from the European Medicines Agency for NX-5948 in CLL Received Fast Track designation from the U.S. FDA for NX-5948 in Waldenstrom's Macroglobulinemia Announced the appointment of John Northcott as Chief Commercial Officer Well capitalized with cash and marketable securities of $609.6 million SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercial

      1/28/25 4:00:00 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Van Houte Hans sold $70,243 worth of shares (6,198 units at $11.33), decreasing direct ownership by 16% to 33,724 units (SEC Form 4)

      4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

      5/2/25 6:18:47 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Hansen Gwenn converted options into 8,956 shares and sold $38,841 worth of shares (3,377 units at $11.50), increasing direct ownership by 10% to 61,516 units (SEC Form 4)

      4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

      4/30/25 7:35:40 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Ring Christine converted options into 7,674 shares and sold $33,286 worth of shares (2,894 units at $11.50), increasing direct ownership by 15% to 37,318 units (SEC Form 4)

      4 - Nurix Therapeutics, Inc. (0001549595) (Issuer)

      4/30/25 7:35:28 PM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Nurix Therapeutics with a new price target

      Leerink Partners initiated coverage of Nurix Therapeutics with a rating of Market Perform and set a new price target of $16.00

      3/17/25 7:40:03 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Nurix Therapeutics with a new price target

      BTIG Research initiated coverage of Nurix Therapeutics with a rating of Buy and set a new price target of $35.00

      12/10/24 8:32:11 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Nurix Therapeutics with a new price target

      BMO Capital Markets initiated coverage of Nurix Therapeutics with a rating of Outperform and set a new price target of $35.00

      12/6/24 7:59:04 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NRIX
    Financials

    Live finance-specific insights

    See more
    • Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

      Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid and deepening with longer time on treatment Nurix intends to advance NX-5948 into pivotal trial(s) in 2025 Company will host a webcast conference today, June 16, 2024, at 9:00 a.m. ET (3:00 p.m. CEST) SAN FRANCISCO, June 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the presentation of updated clinical d

      6/16/24 5:30:00 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)

      SAN FRANCISCO, June 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a webcast and conference call at 9:00 a.m., ET, on Sunday, June 16, 2024, to discuss data from the ongoing Phase 1 clinical trial of NX-5948 that will be presented in an oral session at the European Hematology Association Congress in Madrid, Spain. The oral presentation at EHA2024 will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractor

      6/10/24 7:00:00 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

      Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcast conference call on June 16 following the data presentation at EHA (details to follow) SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (NASDAQ:NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory

      5/14/24 10:00:00 AM ET
      $NRIX
      Biotechnology: Pharmaceutical Preparations
      Health Care